Mumbai, India
Mumbai, India

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India; Belgium, & Surrey in the European Union; and Miami, Florida, in the United States; with manufacturing facilities in Goa , Bengaluru , Baddi , Indore , Kurkumbh , Patalganga , and Sikkim , along with field stations in Delhi, Pune, and Hyderabad. Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.As of 17 September 2014, its market capitalisation was 7px517 billion , making it India's 42nd largest publicly traded company by market value. Wikipedia.


Time filter

Source Type

Patent
Cipla | Date: 2016-08-08

The present invention is concerned with the treatment of Pulmonary Arterial Hypertension (PAH) by administering Paliperidone. The instant invention further relates to use of a pharmaceutical composition comprising Paliperidone, for the treatment of PAH.


Patent
Cipla | Date: 2016-09-06

Described herein are pharmaceutical compositions for inhalation comprising glycopyrrolate, a beta_(2)-agonist, and optionally an inhaled corticosteroid; to a process for preparing such compositions and to the use of such compositions for the prevention and/or treatment of respiratory, inflammatory or obstructive airway disease.


A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.


Patent
Cipla | Date: 2016-10-12

This invention provides a low dose pharmaceutical composition comprising deferasirox or a pharmaceutically acceptable derivative thereof and one or more pharmaceutically acceptable excipients. A unit dose of the pharmaceutical composition comprises from about 50 mg to about 100 mg of deferasirox, from about 150 mg to about 200 mg of deferasirox or from about 260 mg to about 350 mg of deferasirox. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox, may be used to treat chronic iron overload or to treat lead toxicity. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox and deferiprone, may be used to treat lead toxicity. This invention also provides a process for preparing the low dose pharmaceutical composition, the process comprising: dissolving or adsorbing or blending deferasirox and at least one excipient to produce a dispersion of deferasirox; and processing the dispersion to produce a desired dosage form.


Patent
Cipla | Date: 2016-11-03

Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.


Patent
Cipla | Date: 2016-11-03

The present invention relates to stable pharmaceutical compositions of fosaprepitant or a salt thereof in the form of ready-to-use or ready-to-dilute compositions suitable for parenteral administration.


Disclosed herein are method of treating neurodegenerative diseases, including Alzheimers disease, with the anti-histaminic drug betahistine.


The present invention relates to a novel process for the synthesis of everolimus of formula (I) and intermediates thereof.


The present invention relates to pharmaceutical compositions for inhalation which comprise one or more bronchodilators.


Patent
Cipla | Date: 2017-01-18

A device (20) is disclosed for dispensing a fluid supplied from an external fluid source. The device comprises a transducer (32) adapted to receive a fluid from the fluid source, and a collapsible linkage and trip link (502) coupling the transducer and the fluid source. The linkage has a collapsible joint inhibiting discharge of the fluid source when in a locked orientation. The device (20) further comprises a moveable member coupled to the linkage such that inhalation forces on the device cause the linkage to collapse thereby discharging the fluid from the fluid source. The device may further include a dose counter coupled to the fluid source for registering the amount of doses administered from the fluid source.

Loading Cipla collaborators
Loading Cipla collaborators